Bacteriophages and Lysins in Biofilm Control

Łusiak-Szelachowska, Marzanna; Weber‐Dąbrowska, Beata; Górski, Andrzej

doi:10.1007/s12250-019-00192-3

Cited by 97 publications

(92 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These structures consist of communities of microorganisms embedded in self-produced extracellular polymers, which colonize both biological and abiotic surfaces such as catheters, posing a threat for many catheterized patients. Due to the increased cell density and the lack of oxygen and nutrients available to cells in the deepest layers of the biofilms, their metabolic activity is reduced, thus explaining the lower efficacy of antibiotics [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Bacteriophages and Lysins as Possible Alternatives to Treat Antibiotic-Resistant Urinary Tract Infections

et al. 2020

View full text Add to dashboard Cite

Urinary tract infections represent a major public health problem as the rapid emergence of antibiotic-resistant strains among uropathogens is causing the failure of many current treatments. The use of bacteriophages (phages) and their derivatives to combat infectious diseases is an old approach that has been forgotten by the West for a long time, mostly due to the discovery and great success of antibiotics. In the present so-called “post-antibiotic era”, many researchers are turning their attention to the re-discovered phage therapy, as an effective alternative to antibiotics. Phage therapy includes the use of natural or engineered phages, as well as their purified lytic enzymes to destroy pathogenic strains. Many in vitro and in vivo studies have been conducted, and these have proved the great potential for this therapy against uropathogenic bacteria. Nevertheless, to date, the lack of appropriate clinical trials has hindered its widespread clinic application.

show abstract

Section: Introductionmentioning

confidence: 99%

Bacteriophages and Lysins as Possible Alternatives to Treat Antibiotic-Resistant Urinary Tract Infections

et al. 2020

View full text Add to dashboard Cite

show abstract

“…For thermo-stability, the phage was incubated at 40 ºC, 50 ºC, 60 ºC, 70 ºC, and 80 ºC, and sample were collected after 20, 40, and 60 min for phage titration using the DLA method. For pH stability, the phage were added to tubes containing SM buffer of different pH values (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12) and then incubated for 1 h at 37 ºC before phage titration was performed by the DLA method [17].…”

Section: Thermal and Ph Stabilitymentioning

confidence: 99%

Phage JS02, A Putative Temperate Phage, A Novel Biofilm-Degrading Agent for Staphylococcus Aureus

Zhang

Ding

Shahin

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Staphylococcus aureus is a biofilm-producing organism that is frequently isolated from various environments worldwide. Because of the natural resistance of S. aureus biofilm to antibiotics, bacteriophages are considered as a promising alternative for its removal. Results: The bacteriophage vB_SauS_JS02 was isolated from livestock wastewater and showed activity against multidrug-resistant (MDR) S. aureus. The phage vB_SauS_JS02 was morphologically classified as Siphoviridae; it had a broad host range (45 out of 81 strains, 55.6%) and high burst size (52 plaque-forming unit (PFU)/infected cell) and could survive in a pH range of 4 to 11 and a temperature range of 40 ºC to 50 ºC. Bioinformatics analysis showed that the phage genome contained a long double-stranded linear DNA genome of 46,435 base pairs with a G＋C content of 33.1% and had 66 putative open reading frames (ORFs). The predicted protein products of the ORFs were clustered functionally into five groups as follows: replication/regulation, DNA packaging, structure/morphogenesis, lysis, and lysogeny. The phage vB_SauS_JS02 was a temperate phage with a higher inhibiting and degrading activity against planktonic cells (~86% reduction) and S. aureus biofilm (∼68% reduction in biofilm formation). Moreover, the removal activity of the phage vB_SauS_JS02 against both planktonic cells and S. aureus biofilms was even better than that of the antibiotic (ceftazidime). Conclusion: In summary, the present study introduced the phage vB_SauS_JS02 as a potential biocontrol agent against biofilm-producing S. aureus.

show abstract

“…Phage-antibiotic therapy has shown promise for biofilms and in embedded bacteria; phages can enzymatically penetrate the microenvironment created by biofilm-forming cells to infect and kill target bacteria ( Pires et al, 2017 ). Phages, when administered in combination with an antibiotic, can increase the susceptibility of bacteria and reduce plasmid-borne bacterial resistance by targeting plasmid bearing bacteria in the biofilm ( Łusiak-Szelachowska et al, 2020 ). Combined phage and antibiotic therapy with a sequential approach of administering the antibiotic after phage treatment of the biofilm has shown success; initial treatment of the biofilm with phages caused biofilm disintegration, while later administration of the antibiotic prevented biofilm regrowth as well as the emergence of phage-resistant mutants.…”

Section: Introductionmentioning

confidence: 99%

“…Combined phage and antibiotic therapy with a sequential approach of administering the antibiotic after phage treatment of the biofilm has shown success; initial treatment of the biofilm with phages caused biofilm disintegration, while later administration of the antibiotic prevented biofilm regrowth as well as the emergence of phage-resistant mutants. Phages can enable antibiotics to penetrate biofilm layers by degrading the biofilm matrix; phages penetrate into deeper layers of the biofilm, replicating in the lower layers and facilitating the destruction of the biofilm ( Łusiak-Szelachowska et al, 2020 ). Antibiotics administered following biofilm treatment by phages enhance bacterial reduction Akturk et al, 2019 .…”

Section: Introductionmentioning

confidence: 99%

“…The ability of endolysins to digest the bacterial cell wall when applied exogenously offers the opportunity for their deployment as potential antibacterial agents, to target and kill pathogenic bacteria, potentially without harming the normal microflora due to specificity of enzyme activity ( Haddad Kashani et al, 2017 ). The chances of bacteria developing resistance toward endolysins are low since endolysins target cell wall molecules essential for bacterial viability ( Łusiak-Szelachowska et al, 2020 ). Phage-derived endolysins are promising candidates for treating secondary bacterial infections or multi-drug resistant infections ( Imanishi et al, 2019 ; Kim et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?

et al. 2020

View full text Add to dashboard Cite

Secondary bacterial infections manifest during or after a viral infection(s) and can lead to negative outcomes and sometimes fatal clinical complications. Research and development of clinical interventions is largely focused on the primary pathogen, with research on any secondary infection(s) being neglected. Here we highlight the impact of secondary bacterial infections and in particular those caused by antibiotic-resistant strains, on disease outcomes. We describe possible non-antibiotic treatment options, when small molecule drugs have no effect on the bacterial pathogen and explore the potential of phage therapy and phage-derived therapeutic proteins and strategies in treating secondary bacterial infections, including their application in combination with chemical antibiotics.

show abstract

Bacteriophages and Lysins in Biofilm Control

Cited by 97 publications

References 45 publications

Bacteriophages and Lysins as Possible Alternatives to Treat Antibiotic-Resistant Urinary Tract Infections

Bacteriophages and Lysins as Possible Alternatives to Treat Antibiotic-Resistant Urinary Tract Infections

Phage JS02, A Putative Temperate Phage, A Novel Biofilm-Degrading Agent for Staphylococcus Aureus

Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?

Contact Info

Product

Resources

About